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Abstract 
 
Sickle cell disease (SCD) is an inherited disorder of hemoglobin structure that has no established 
cure in adult patients. Cure has been achieved in selected children with sickle cell anemia (SCA) 
using allogeneic bone marrow transplantation or cord blood transplantation. SCD is essentially a 
triumvirate of (1) pain syndromes, (2) anemia and its sequelae and (3) organ failure, including 
infection. Pain, however, is the hallmark of SCD and dominates its clinical picture throughout 
the life of the patients. The prevalence of these complications varies with age from infancy 
through adult life. However, pain, infections and anemia requiring blood transfusion occur 
throughout the life span of affected patients. The overall medical care of patients with SCD in 
developed countries has improved such that their life expectancy has almost doubled since 1951. 
Currently, there are at least five major approaches for the general management of SCD and its 
complications. These include (i) symptomatic management, (ii) supportive management, (iii) 
preventive management, (iv) abortive management, and (v) curative therapy. 
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Introduction 
 
Hemoglobinopathies are inherited disorders of the structure and/or function of 
hemoglobin (Hb). They are broadly divided into two major groups: structural variants and 
thalassemias. Structural variants are, most commonly, the result of single base mutations in the 
globin genes. Thalassemias are characterized by decreased synthesis of any one or more of the 
globin chains. 
The sickle mutation is the result of a single base change (GAG→ GTG) in the sixth codon of 
exon 1 of the β-globin gene responsible for the synthesis of the β-globin polypeptide of the Hb 
molecule (α2β2). This change, in turn, results in replacement of the normal glutamic acid (E/Glu) 
with valine (V/Val) at position 6 of the β-globin chain and the formation of sickle Hb [1-3]. 
Over two million U.S. residents are estimated to be either heterozygous or homozygous 
for the genetic substitution. Most of those affected are of African ancestry or self-identify as 
Black; a minority are of Hispanic or southern European, Middle Eastern, or Asian Indian descent 
[4]. It is estimated that between 70,000 and 100,000 African Americans have SCD. Although 
SCD is associated with major morbidity, currently more than 90 percent of children with SCD in 
the United States and the United Kingdom survive into adulthood [5-7]. However, their lifespan 
remains shortened by two or three decades compared to the general population [8, 9]. 
Classification of Sickle Cell Disorders 
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 Sickle cell disease comprises a group of clinically significant hemoglobinopathies in 
which the sickle gene is inherited from at least one parent. Sickle cell anemia (SCA) is the 
homozygous state where the sickle gene is inherited from both parents. Sickle cell syndromes 
also result from the co-inheritance of the sickle gene with Hb C gene giving rise to Hb SC 
diseases, with β-thalassemia genes (β0 or β+) giving rise to sickle - β0-thalassaemia or sickle - β+-
thalassemia respectively or with other β-globin structural variants giving rise to other 
combinations such as HbSO Arab, HbSD disease, and so. The most prevalent SCD types include 
homozygous Hb SS and the compound heterozygous conditions HbSβ0-thalassemia, HbSβ+-
thalassemia, and Hb SC disease. Hb SS and HbSβ0-thalassemia are clinically very similar and 
therefore are commonly referred to as SS or SCA; these genotypes are associated with the most 
severe clinical manifestations. Certain complications of SCD may be more common in one 
category than another. Thus, frequent painful crises, severe anemia that requires blood 
transfusion and acute chest syndrome (ACS) are more common in SCA than other types of SCD. 
Sickle retinopathy and otologic disorders, on the other hand, are more common in Hb SC 
disease than in SCA. It must be emphasized that the order of severity in SCD is based on 
population statistics. Thus, if one compares the overall clinical picture of 100 patients with SCA, 
for example, with that of 100 patients with Hb SC disease then the latter will be milder as far as 
frequency of painful episodes, morbidity and mortality are concerned. On the individual basis, 
however, there are exceptions. Thus, an individual patient with SCA may have a mild disease 
whereas an occasional patient with S-β+-thalassemia may have a severe disease. 
Genetics and Epigenetics 
Sickle cell syndromes can also be divided into subcategories depending on the α 
genotypes and β haplotypes [10-12]. About 65% of patients with SCA have normal α genotypes 
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(βSβS; αα/αα), 30% have one α gene deleted (βSβS; -α/αα), and the remaining 5% have two α 
genes deleted (βSβS; -α/-α).  The effect of α gene deletion on the clinical picture of sickle cell 
syndromes is controversial. Generally speaking, α gene deletion is associated with milder anemia 
[13] and less blood transfusion. The increased Hb level associated with α gene deletion, 
however, presumably increases the blood viscosity, which is often accompanied by increased 
frequency of painful crises [14, 15] and vaso-occlusive episodes such as avascular necrosis 
(AVN) [16, 17]. Recently, Renoux et al [18] observed increased frequency of crises in 
children with alpha-thalassemia but it was not explained by increased blood viscosity. 
Instead, children with alpha-thalassemia had greater RBC deformability and RBC 
aggregation. The number of patients studied, however, was relatively small and the 
diagnosis of avascular necrosis was not ruled out [18]. The effect of α gene deletion on the 
clinical picture is best illustrated in SCA with two α gene deletions. Table 1 lists the unique 
features of this type of SCD [19, 20]. Noteworthy is that HbA2 is elevated in SCA with two α 
gene deletions, a finding that confuses this diagnosis with Sβ0 thalassemia that is, typically, also 
associated with elevated HbA2 levels. The clinical picture, family history, hematological data 
and molecular diagnostics can differentiate the two diagnoses [20]. 
 β-Haplotypes refer to the nucleotide sequence 5’ and 3’ to the sickle gene. Three major 
types have been described in Africans and African Americans [11]. These are the Senegalese 
(Sen), Benin (Ben) and Central African Republic (CAR) haplotypes. The significance of these 
haplotypes pertains to their effect on Hb F production. It has been established that the higher the 
Hb F level, the milder is the SCA [15, 21]. Again, these conclusions are based on population data 
and may not apply to an individual patient. 
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Epigenetic factors that could affect phenotypic expression include the environment, 
aging, drugs/pharmaceuticals and diet. The exact mechanism of action of epigenetic factors at 
the molecular level is not well known. It seems that some drugs may cause methylation or 
demethylation of DNA or modification of histones resulting in activation or deactivation of 
certain genes that could affect the phenotypic expression of the gene in question [22]. 
 
 
Genetic Markers  
 Sickle cell disease is a complex genetic disorder characterized by intricate 
genotypic/phenotypic interactions that include correlations among multiple genetic and 
environmental markers and modifiers. Genetic markers may predict the severity of the disease 
and the possible or probable incidence of certain complications. This, in turn, allows for the 
implementation of certain therapeutic measures that may prevent or ameliorate the severity of 
some of these complications. Traditional approaches to identify genetic markers have included 
studies of the transgenic sickle cell mouse and natural history studies and family pedigrees [23, 
24]. With the advent of the Human Genome Project, novel genetic polymorphisms associated 
with disease have been identified, thus allowing for the performance of genetic association 
studies [24-31]. 
Although these findings are novel and interesting, their validity and utility in predicting 
and treating the clinical complications of SCD should be confirmed by large controlled multi-
institution studies. The studies performed to date are too small to make definite conclusions. 
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Other Factors 
 In addition to the factors mentioned above, there is growing evidence that psychosocial 
and environmental factors precipitate vaso-occlusion and affect the frequency and severity of 
painful episodes. Physical stress, trauma, dehydration and infections are such known factors. 
Clinical Complications of Sickle Cell Disease 
Major complications of SCD include three sets of clinical adverse effects: (1) pain 
syndromes, (2) hemolytic anemia and its sequelae and (3) organ damage/failure. The prevalence 
of these complications varies with age from infancy through adult life as shown in Figure 1. 
However, pain, infections and anemia requiring blood transfusion occur throughout the life span 
of affected patients. 
Pain Syndromes 
The Acute Painful Vaso-occlusive Crisis (VOC)   
 
Sickle cell pain has unique features. Pathophysiologically, it is nociceptive (ie, secondary 
to tissue damage). It may be acute or chronic, somatic or visceral, unilateral or bilateral, 
localized or diffuse and mild, moderate or severe [32]. Typically, VOCs affect long bones and 
joints, with the low back frequently reported site of pain [33]. Other regions of the body, 
including the scalp, face, jaw, abdomen, and pelvis, may be involved. A severe acute sickle cell 
painful episode has been defined as one that requires treatment in a medical facility with 
parenteral opioids for 4 or more hours [34, 35]. The occurrence of three or more such crises 
indicates that the affected patient has severe SCD. The words most often used to describe sickle 
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pain include “throbbing,” “sharp,” “dull,” “stabbing,” and “shooting,” in decreasing order of 
frequency [33]. 
Objective signs of a VOC, such as fever, leukocytosis, joint effusions, and tenderness, 
occur in about 50% of patients at initial presentation [13]. During the evolution of the VOC, 
however, objective laboratory signs become evident in most patients, provided that these 
parameters are determined serially [36]. The VOC that requires hospitalization appears to evolve 
along four distinct phases: prodromal, initial, established, and resolving [37]. Each phase may be 
associated with certain clinical and laboratory findings. As the pain of a VOC intensifies, the 
percentage of dense RBC increases with a concomitant decease in RBC deformability. Some 
patients develop hyperhemolysis during the evolution of the VOC, with decrease in Hb level and 
increase in the reticulocyte count [37]. As pain resolves, the pattern is reversed, with a decrease 
in the number of dense red cells and an increase in RBC deformability [36]. 
Chronic sickle cell pain 
Avascular Necrosis 
 Avascular necrosis (also called ischemic necrosis or osteonecrosis) is the most commonly 
observed complication of SCD after the number of VOCs in adults. Although it tends to be most 
severe and disabling in the hip area, it is a generalized bone disorder in that the femoral and 
humeral heads as well as the vertebral bodies may be equally affected. The limited terminal 
arterial blood supply and the paucity of collateral circulation make these three areas especially 
vulnerable to sickling and subsequent bone damage.  In the Cooperative Study of Sickle Cell 
Disease (17) that included 2804 patients,  with SCA and α-gene deletion had a higher incidence 
of AVN because the relatively high hematocrit increases blood viscosity and thus, enhances 
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microvasculopathy in the aforementioned anatomic sites [16, 17]. The mean corpuscular volume 
(MCV) and AST levels were reported to be negatively correlated with avascular necrosis 
especially in patients with homozygous alpha gene deletion [17].  In a study involving about 
100 patients with SCA, Lemonne et al. [38] found no difference in blood viscosity between 
patients with and those without osteonecrosis, despite difference in hematocrit/Hb. 
Together, all these findings suggest that Hb seems to have a negative effect on the 
frequency of AVN irrespective of its effect on viscosity. The roles of Hb/Hct, viscosity, 
deformability and aggregation in the pathophysiology of certain complications of SCD need 
further studies. 
 Medical treatment of AVN is symptomatic and includes providing non-opioid and/or 
opioid analgesics for pain relief as well as physical therapy. Advanced forms of the disease 
require total bone replacement. Core decompression in the management of AVN appears to be 
effective if done in the early stages of AVN [39].  This, however, was not supported by a 
prospective randomized multi-center comparing physical therapy alone with core decompression 
and physical therapy for femoral head AVN in 46 patients with SCD [40]. Physical therapy alone 
appeared to be as effective as hip core decompression followed by physical therapy in improving 
hip function and postponing the need for additional surgical intervention at a mean of three years 
treatment. Results of hip arthroplasty in patients with SCA are not as encouraging as results of 
arthroplasty performed for arthritic hip [41].  Placement of an internal prosthesis may be difficult 
owing to the presence of hard sclerotic bone in patients with SCD. Other problems associated 
with hip arthroplasty in these patients include an increased incidence of infection [42, 43], a 
failure rate of about 50% and a high morbidity due to loosening of both cemented and 
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uncemented prosthesis. Recent techniques of arthroplasty may improve the life expectancy of hip 
prostheses [44]. 
Leg ulcers 
Leg ulceration is a painful and sometimes disabling complication of SCA that occurs in 5 
to 10% of adult patients. The most common site for the appearance of leg ulcers is the distal third 
of the leg, especially on the inner area, just above the ankle and over the medial melleoli. 
Ulceration involves the skin and underlying tissues of the involved areas. The deeper the ulcer 
the more severe. Leg ulcers are classified into stages depending on their depth and not surface 
area. Severe pain may necessitate the use of opioid analgesics. The use of topical analgesics 
seems to be effective in relieving pain and decreasing the use of oral analgesics, especially 
opioids [45].  
Leg ulcers are more common in males and older patients, and less common in patients 
with α-gene deletion, high total Hb level or high levels of Hb F [19]. Leg ulcers seem to be more 
common in patients who are also carriers of the CAR β-gene cluster haplotype [46]. As was 
mentioned above leg ulceration seems to be associated with priapism, pulmonary hypertension 
and death in a subtype of SCD characterized by high levels of lactate dehydrogenase (LDH) as a 
marker of hyperhemolysis. 
Treatment of leg ulcers includes wound care using wet to dry dressings soaked in saline 
or Burrow’s solution. With good localized treatment, many ulcers heal within a few months. Oral 
zinc sulfate therapy (660 mg per day) may be beneficial for some patients [47]. However, a 
Cochrane review [48], showed that oral zinc for arterial or venous leg ulcers due to causes other 
than SCD had no significant difference compared to placebo. Leg ulcers that persist more than 6 
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months present a challenge to the treating physician and the patient. In addition, survival of 
patients with chronic leg ulcers seems to be decreased compared to patients without leg ulcers 
[49]. 
 Certain modalities for the management of leg ulcers that are not commonly used in SCD 
include topical application of platelet-derived growth factor prepared either autologously 
(Procuren) [50] or by recombinant technology (Regranex) [51], topical sodium nitrite for 
chronic leg ulcers [52],  and the use of cultured skin grafts [53]. In addition, mānuka honey 
from New Zealand has been reported to heal diabetic foot ulcers [54, 55]. Amputation, a last 
resort for recalcitrant and severely painful ulcers, is rarely used [56, 57]. 
 The induction of Hb F production by hydroxyurea (HU) [34] would imply that it may 
prevent or heal leg ulcers in patients with SCD. However, HU has been reported to be associated 
with leg ulcers in patients with myeloproliferative disorders [58, 59]. Whether the same 
association exists in patients with SCD is controversial. Leg ulcers were a common complication 
among 123 adult patients treated with HU in a retrospective French study [60]. Although 
controlled studies have not been reported to support the role of Hb F induction in the 
management of leg ulcers, future randomized, multicenter trials of HU may provide further 
information on this subject. 
 
Pain between Crises 
Some patients with SCD complain of pain between VOCs and take opioids with or 
without nonopioid analgesics on a chronic basis. They have no evidence of precipitating cause 
such as infection, dehydration, or ischemia. Many of these patients are often referred to as having 
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chronic pain despite the fact their pain is not similar to other chronic pain syndromes such as low 
back pain in the general population, fibromyalgia, osteoarthritis, migraine, etc. 
Neuropathy and neuropathic pain 
Neuropathy and neuropathic pain are not the same and not all patients with neuropathy 
have pain. Neuropathic pain is not well documented as a complication of SCD. The scales to 
assess neuropathic pain are different than those used in assessing sickle cell pain and their use 
has not been validated in SCD. Neuropathy, especially peripheral neuropathy, has been reported 
in patients with SCD, albeit uncommonly. Mental nerve neuropathy (AKA numb chin syndrome) 
is the most commonly reported neuropathy in SCD usually associated with VOC. More studies 
are needed to determine the prevalence of neuropathy and neuropathic pain in patients with SCD 
and to find whether these are complications of the disease itself or due to co-morbidities [61]. 
Hematological Manifestations   
 Hemolytic anemia and its sequelae 
Sickle cell anemia is characterized by normochromic, normocytic anemia with a mean 
Hb of 7.8 ± 1.13 and a mean corpuscular volume (MCV) of 90 fl.  The presence or absence of α-
gene deletion has an effect on the anemia, the indices and the hemoglobin electrophoresis 
pattern.  Thus, patients with SCA and homozygous α-thal 2 (βSβS; -α/-α) have milder anemia, a 
lower reticulocyte count, a low MCV and a high Hb A2 level.  Both the white blood cell and 
platelet counts are increased in SCA due to increased marrow activity secondary to chronic 
hemolysis and, in the case of SCA, to "autosplenectomy", where platelets are not stored in the 
spleen.  Normally, about one-third of circulating platelets are stored in the spleen and patients 
with splenectomy typically have high platelet counts.  Patients with splenomegaly (S-β-
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thalassemia, Hb SC disease and SCA with α-thalassemia) typically have low or low-normal 
platelet counts, depending on the degree of splenomegaly. 
Patients with S-β0-thalassemia have a hematological picture that is characterized by 
microcytosis, hypochromia, high Hb A2 levels and variable Hb F values. The anemia in Hb S-β+-
thalassemia is mild and usually with Hb level greater than 10 g/dL. Hb SC disease is typically 
characterized by microcytic and hyperchromic RBC indices. 
In addition to the chronic hemolytic anemia typical of SCD, patients with SCA may 
develop other types of anemia. Hyperhemolysis (or hyperhemolytic crisis) is characterized by a 
marked drop in Hb with evidence of increased red blood cell destruction in the absence of other 
identifiable causes such as splenic or hepatic sequestration. The decrease in Hb should be ≥20% 
from baseline and the increase in reticulocyte by 25% or presence of nucleated RBC in the 
peripheral smear. Moreover, there should be evidence of hemolysis [increased LDH, 
unconjugated bilirubin, or aspartate aminotransferase (AST)], compared with baseline without 
recovery from bone marrow suppression [62].   Hyperhemolysis may be caused by infection 
(example, mycoplasma pneumonia), a co-existent G6PD deficiency with exposure to oxidant 
stress or by a delayed hemolytic transfusion reaction.  Aplastic crisis characterized by a decrease 
both in Hb and reticulocyte values, is most commonly caused by infection, both bacterial and 
viral.  Megaloblastic crisis is occasionally seen in those patients who become folate-deficient 
because of poor dietary habits and no folic acid supplementation.  Iron deficiency anemia may 
complicate SCA, especially in young menstruating women who refuse blood transfusion if 
needed.  Whether iron deficiency anemia has a salutary effect on the phenotypic expression of 
SCA because of impaired Hb S polymerization secondary to decreased mean corpuscular 
hemoglobin concentration, or not, is an issue that is not settled in the literature. 
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 Hyperviscosity 
Whole blood viscosity is a function of the number, deformability, and aggregability of 
erythrocytes, as well as of the quantity and nature of plasma proteins (see the review by Connes 
et al in this special issue of Clinical Hemorheology and Microcirculation). In SCD, viscosity 
is dominated by Hb S gelation and the presence of dense sickle cells. The hyperviscosity 
syndrome in SCD (and other hemoglobinopathies) occurs most frequently post-transfusion [63]. 
Transfusional Hemosiderosis 
Transfusional hemosiderosis or iron overload refers to an increase in total body iron due 
to multiple blood transfusions of  ≥20 units or  ≥200mL/kg of red blood cells and serum ferritin 
level of  >1000 ng/mL and transferrin saturation >50% on ≥3 serial determinations in the steady 
state or measurement of abnormally increased iron by liver biopsy, magnetic resonance imaging 
(MRI) T2∗ or Ferriscan [64-66]. 
Organ Damage/Failure    
 Almost all organs are affected in SCD in general and SCA in particular. These were 
recently reviewed in a few publications [67-69]. The major systems affected and their 
management will be summarized below. 
             Infection 
Sickle cell anemia has an unusual relationship to certain infectious agents.  Individuals 
with sickle trait are resistant to infection by Plasmodium falciparum but patients with SCA are 
susceptible.  Individuals with Fy (a-b-) RBC are resistant to infection by other types of malarial 
parasites.  Several acquired abnormalities render patients with SCD immune compromised and, 
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hence, susceptible to a number of infections that are a major cause of mortality and morbidity in 
these patients. The increased susceptibility of patients to infection with the polysaccharide-
encepsulated bacteria (S. pneumoniae and H. influenzae) is secondary to the absence of splenic 
function.  Cellular immunity may be compromised by transfusion-related iron overload and 
abnormalities in B-cell immunity may explain antigen processing defects.  Infections due to E. 
coli are usually associated with urinary tract infection in adult patients.  Patients with SCA are 
susceptible to osteomyelitis secondary to S. typhimurium in addition to the usual causes of 
bacterial osteomyelitis such as S. aureus. The susceptibility to infection by Salmonella may 
reflect the ability of this organism to flourish in partially necrotic bone [70]. 
         Neurological complications 
 These include cerebrovascular accidents (strokes), transient ischemic attacks, silent 
infarcts and neurocognitive impairment. Cerebrovascular accidents include infarctive stroke 
mostly in children, hemorrhagic stroke mostly in adults and moyamoya. Infarctive stroke is an 
acute neurological syndrome resulting from impaired cerebral blood flow without evidence of 
hemorrhage lasting more than 24 hours. Hemorrhagic stroke is intracranial hemorrhage causing 
neurologic symptoms and signs. Moyamoya is abnormal vascular network (“puff of smoke” 
appearance) indicative of collateral circulation secondary to stenosis or occlusion of large 
cerebral arteries [71, 72]. 
 Transient ischemic attack is a brief episode of neurologic dysfunction caused by focal 
brain ischemia, with clinical symptoms typically lasting less than 1 hour, and without subsequent 
evidence of cerebral infarction [71, 73]. Silent cerebral infarcts (SCI) are changes on MRI of 
brain consistent with infarction without associated history of neurologic symptoms or abnormal 
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neurological exam [71, 74]. Most SCI are localized in the deep white matter and less commonly 
in the subcortical grey matter structures. In the Comprehensive Study of SCD (CSSCD), about 
25% of the children with SCI had new and/or enlarging lesions on follow-up MRI scan [75]. In 
comparison only 2.5% of the children without SCI, had new and/or enlarging lesions on follow‐
up MRI scan.  The SIT trial showed that regular blood transfusion to children aged 5–14 years 
with SCI reduced the risk of reinfarction, both overt stroke and silent infarcts [76].  
          Neurocognitive impairment is defined by the presence of abnormal nonverbal function 
assessed by the Wechsler Adult Intelligence Scale III Performance IQ Index in adult patients 
with SCA who are neurologically asymptomatic. This impairment is most likely secondary to 
cerebral hypoxemia undetectable by standard neuroimaging studies [77, 78]. 
Ophthalmological Complications 
 The most important and serious ophthalmological complications of SCD include the 
following: 
 Proliferative sickle retinopathy which is neovascular fronds that emerge from the retinal 
vasculature at the interface of perfused and non perfused retina in response to vascular growth 
factors produced by ischemic retina. The neovascular tissue is predisposed to hemorrhage and 
vitreoretinal traction forces. Although these pre-retinal neovascular formations, which may 
resemble and are called sea fans, are bright red when viable, they appear white when 
autoinfarcted or caused to involute by laser photocoagulation [79]. 
 Retinal detachment is separation of the retina from the choroid and eye wall due to holes 
in the retina and traction on the retina by vitreous bands and condensed pre-retinal membranes 
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(usually as sequelae of proliferative sickle retinopathy). Retinal detachment is the most severe 
complication (Stage V) of proliferative sickle retinopathy [80]. 
 Vitreous hemorrhage is bleeding into the vitreous cavity caused by mechanical stress 
(from trauma or normal vitreous movement) on the delicate neovascular fronds growing from the 
retina into the vitreous chamber. Vitreous hemorrhage is a severe complication of proliferative 
sickle retinopathy [81]. 
Cardiac Complications 
          High output failure, right heart and/or congestive heart failure, cardiac hemosiderosis and 
cardiomegaly are known manifestations of SCD. Recent evidence suggests that myocardial 
ischemia may occur as well and myocardial infarction has been reported [82]. Mitral valve 
prolapse was reported to have high prevalence (23%) in SCD [83]. This finding, however, was 
not confirmed by another group [84]. The signs and symptoms of mitral valve prolapse (chest 
pain, fatigue, syncope, palpitations, etc.) overlap with those of SCD and may elucidate the 
protean manifestations of SCD in case there is an association between these two disorders. 
Pulmonary Complications 
  Acute Chest syndrome 
 The incidence of ACS is age and genotype dependent, with no difference between sexes. 
It is approximately three times more common in young children than in adults but more severe in 
adults [85, 86]. Acute chest syndrome is most common in SCA, sickle β0-thalassemia, Hb SC 
disease, and sickle β+thalassemia in decreasing order of frequency. Coexistent α-gene deletion, 
PLT count, and mean corpuscular volume of RBCs do not appear to affect the incidence of ACS 
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[86]. The incidence of ACS decreases in the presence of high Hb F level and severe anemia but 
is directly proportional to the steady state white blood cell count [86]. Acute chest syndrome is 
closely associated with VOCs, especially in adults [87, 88]. It occurs in approximately 50% of 
hospitalized patients with SCA for VOC [87, 89-91]. These episodes account for 15% of acute 
admissions and are potentially fatal [92-94]. Moreover, ACS appears to be the most common 
cause of death among patients and second to VOC as the most common cause of hospitalization 
of patients with SCD [95-98]. Although ACS is usually self-limited and resolves with treatment, 
it can be associated with respiratory failure, with a mortality rate of 1.8% in children and 4.8% in 
adults [87, 99]. 
 Causes of ACS include pneumonia, bone marrow fat embolism, pulmonary infarct due to 
in situ sickling, rib/sternal infarction, infection, and pulmonary embolism (PE) (149-151). 
Approximately 50% of patients with ACS have no identifiable etiology [87]. Pulmonary bone 
marrow fat embolism in patients with SCA appears to be more common than previously thought 
[87, 99]. The characteristic clinical picture is that of severe bone pain, usually in long bones, 
followed by dyspnea, hypoxia and fever. Tissue infarction of the bone marrow within long bones 
appears to generate a source of fat and necrotic tissue that has been demonstrated in the lung on 
autopsy. 
 Diagnostic work-up should include serial chest radiographs, cultures of sputum and 
blood, monitoring of arterial blood gases and Hb level, ventilation and perfusion (V/Q) scans, 
analysis of induced sputum, bronchial washings, and analysis of urine for fat globules, and ruling 
out thrombophlebitis in the pelvis or lower extremities. The diagnosis of fat embolism entails the 
identification of fat-laden macrophages in induced deep sputum, or better by bronchoalveolar 
lavage fluid obtained by bronchoscopy [87, 100]. 
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 The management of ACS involves multiple modalities to prevent possible 
catastrophic outcomes. The most important aspect of management is to maintain adequate 
ventilation. In mild cases, incentive spirometry may be sufficient to achieve this. However, 
in severe cases, mechanical ventilation in the intensive care unit is essential. 
 Once adequate ventilation is maintained, specific treatment includes oxygen, 
antibiotics, simple blood transfusion or exchange transfusion, judicious use of analgesics, 
bronchodilators, careful hydration, and possible vasodilators. Incentive spirometry 
prevents splinting and atelectasis and may actually prevent ACS in patients with rib 
infarction [101]. Intravenous antibiotics are indicated because it is difficult to rule out 
pneumonia or infected lung infarcts. 
A combination of a third-generation cephalosporin and a macrolide or a quinolone 
antibiotic should be used to cover typical and atypical pathogens. Simple transfusion or 
exchange transfusion is indicated in patients with worsening respiratory function. The 
beneficial effects of blood transfusion may not be due simply to decreasing the proportion 
of sickled RBCs; other mechanisms may be involved. These include (1) an 
immunomodulatory mechanism by which inflammatory cytokines (interleukin [IL]-8 in 
particular) bind to the Duffy antigen present on transfused RBCs but often absent on 
RBCs of Africans and African Americans [102]; and (2) the albumin that is present in 
transfused units or used in blood exchange may bind free fatty acids, thus neutralizing 
their damaging effect on the pulmonary endothelium. 
 
                  Pulmonary Hypertension 
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 Pulmonary hypertension is increased blood pressure in the pulmonary vasculature (both 
micro & macro vasculature). Clinical picture includes dyspnea, palpitations, pain (chest and 
abdomen), syncope, cyanosis, edema, fatigue and heart failure. The World Health Organization 
(WHO) classifies pulmonary hypertension into five groups. Among these the pulmonary arterial 
hypertension (PAH) and the pulmonary venous hypertension (PVH) are the most common and 
most important in SCD. 
 The pathophysiology of PAH includes two mechanisms: vascular obstruction and intimal 
hyperplasia. The vasoconstriction is due to decreased nitric oxide bioavailability and increased 
production of vaso-constrictors such as endothelin [103]. Intimal hyperplasia is the result of the 
hypoxia response pathway [104]. Specifically, hypoxia induced factors α and β (HIF-α and HIF-
β) translocate to the nucleus across the cell membrane. The α/β complex activates the 
transcription of genes that increase cell proliferation and inflammation thus causing intimal 
hyperplasia and vaso-occlusion.  The PVH, on the other hand, is due to left ventricular failure. 
 Pulmonary hypertension is technically defined by a mean pulmonary artery pressure 
(MPAP) ≥ 25 mmHg which can be determined by echocardiography. In order to determine 
whether it is PAH or PVH, however, depends on the mean pulmonary capillary wedge pressure 
which cannot be determined by echocardiography but requires right heart catheterization (RHC). 
PAH is characterized by MPAP ≥ 25 mmHg and capillary wedge pressure ≤ 15 mmHg whereas 
in PVH the capillary wedge pressure is > 15 mmHg. 
 Treatment of pulmonary hypertension depends on its etiology. Thus the treatment of 
PVH targets the management of left ventricular failure. Treatment of PAH includes the use of 
vasodilators. This worked in PAH in the general population but not in PAH in patients with 
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SCD. For now management of PAH in SCD includes blood transfusion and HU. More studies 
and controlled trials are needed to determine the appropriate treatment of the PAH of SCD. 
Genitourinary Complications 
 Table 2 lists the major genitourinary manifestations of SCD. Urinary tract infection is 
usually caused by E. coli and is more common in females than in males.  Its increased frequency 
in SCD may relate to renal infarction or immunodeficiency.  The hypoxic, acidotic and 
hypertonic microenvironment of renal medulla causes sickling of red cells in the vasa recta 
leading to infarction of the renal medulla, hyposthenuria and hematuria (gross or microscopic).  
Inability to acidify the urine after an acid load can also occur.  These tubular defects of the 
kidney (hematuria, hyposthenuria) occur not only in patients homozygous for the sickle gene, but 
in heterozygotes as well (AS, SC, SD, SO, etc.). Hematuria may be due to acute renal papillary 
necrosis, urinary tract infection, and less commonly to glomerulonephritis, obstruction, analgesic 
toxicity, mycobacterial infection, nephrolithiasis, tumor (renal cell carcinoma or medullary cell 
carcinoma), arterio-venous malformations, and vasculitis [105]. Hematuria, especially gross 
hematuria, may be the first sign of renal medullary carcinoma.  Enuresis occurs in children.  
Potassium excretion is also impaired and episodes of hyperchloremia acidosis have been 
reported.  Papillary necrosis seems to be more common in Hb SC disease.  Hyperuricemia in 
SCA is due to increased marrow activity with consequent enhanced purine metabolism and to an 
acquired defect in the renal tubules.  Gout has been described in a few patients. 
 Nephrotic syndrome occurs infrequently with or without hypertension. Microscopic 
hematuria, proteinuria, hypertension and the nephrotic syndrome are markers of incipient end-
stage renal failure.  The pathologic lesion is usually glomerulosclerosis.  Once chronic renal 
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failure sets in, patients require chronic hemodialysis and are candidates for kidney 
transplantation.   
 Acute renal failure is characterized by an abrupt decline in renal function resulting in an 
inability to excrete metabolic wastes and maintain proper fluid and electrolyte balance [106, 
107]. Chronic renal failure is an irreversible and usually progressive reduction in renal function 
in which both kidneys have been damaged to the extent that they are unable to adequately 
remove the metabolic products from the blood and regulate the body’s electrolyte composition 
and acid-base balance. End stage renal disease (ESRD) is the final stage in chronic renal 
insufficiency and, by definition, requires dialysis or renal transplantation to prevent death [108]. 
               Priapism 
Priapism occurs when sickle cells congest the corpora and prevent emptying of blood from the 
penis. It is a common complication of SCD, affecting 35% of boys and men [109]. It is most 
common in patients with SCA, who account for approximately 80% to 90% of reported cases 
[110-113]. However, it does occur in males with all forms of SCD including Hb SC disease, all 
types of sickle thalassemia, and in those with sickle trait [110, 114]. In one survey, a single 
episode of priapism was reported by 31% to 64% of patients, mostly children; approximately 
50% of all patients had recurrent episodes, from 2 to 50 times or more, and the estimated mean 
duration of an episode was 125 minutes (range 50–480 minutes) [112, 113, 115, 116]. Priapism 
is not unique to SCD; it could be secondary to trauma, infection, neoplasm, hemoglobinopathies 
other than SCD, polycythemia, other hemolytic disorders, or hematologic malignancies [117-
121].  
23 
 
                Clinically, priapism may be stuttering, minor, or major. Stuttering priapism is the 
occurrence of short, repetitive, and reversible painful episodes with detumescence occurring 
within a few hours after the onset of erection. This pattern has a good prognosis and is associated 
with normal sexual function and rarely requires medical intervention.  The prevalence of 
stuttering priapism varies from approximately 2% of men with SCD according to some 
investigators [113] to 40% to 60% of men and boys with SCD according to others [115, 122].  
             Management of priapism is highly controversial. Controlled studies are lacking, 
therapeutic approaches are controversial and often conflicting, and medical and surgical 
therapies fail in most patients. Minor episodes of priapism and stuttering priapism usually last 
less than 4 hours and are often treated at home with analgesics, benzodiazepines, or 
pseudoephedrine and do not require treatment at the ED or hospital. Patients are advised to report 
to the ED if an episode lasts longer than 4 hours. Initial treatment in the ED should include 
hydration and opioid analgesics. Catheterization of the urinary bladder may be indicated to 
promote emptying. If these measures fail to cause detumescense, penile aspiration and 
epinephrine irrigation should be performed. Mantadakis et al. [123] recommend that aspiration of 
blood from the corpora cavernosa, followed by irrigation with dilute epinephrine, should be the 
initial therapy used for patients with SCA and prolonged priapism.  
            Simple transfusion or exchange transfusion may be performed for patients whose 
priapism does not respond to aspiration and irrigation procedures and persists for 24 hours or 
longer [124-126]. An association between blood exchange transfusion for priapism due to SCD 
and severe neurologic events including severe headache, seizures, focal neurological deficits, and 
obtundation has been made [127, 128]. This association has been named the ASPEN syndrome 
(Association of Sickle cell disease, Priapism, Exchange transfusion, and Neurologic events). 
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However, analysis of their data shows that the Hb level after blood exchange was much greater 
than the patient’s baseline level. Thus, the neurologic complications were most likely due to 
transfusion- induced hyperviscosity. A larger study of blood exchange transfusion in patients 
with priapism, which maintained the post-exchange Hb level similar to baseline values, showed 
no neurologic complication in any of the patients [129]. Patients responding to transfusion 
therapy usually experience detumescence within 24 to 48 hours after the procedure. If 
detumescense does not occur within 24 hours after the completion of blood exchange 
transfusion, surgical intervention should be considered. Surgical intervention includes various 
shunt procedures between the cavernosa and the spongiosum [130, 131]. Without intervention, 
severe priapism results in impotence in >80% of patients. The combination of transfusions and 
surgery can decrease this to 25% to 50%. Patients who become impotent may benefit from 
psychologic counseling and the insertion of a prosthetic penile implant.  
Hepatobiliary Complications 
         Hepatic sequestration is sequestration of red blood cells in hepatic sinusoids, leading to 
liver enlargement and decreased Hb concentration by ≥2 g/dL from baseline with reticulocytosis, 
without other explanation and liver enlargement of ≥3 cm for children and ≥5 cm for adults 
(from previous physical examination) without other explanation [132, 133]. Intrahepatic 
cholestasis is intrahepatic obstruction of bile formation or flow leading to hyperbilirubinemia. In 
SCD, this syndrome may occur in the context of hepatic sequestration with the addition of 
striking hepatic dysfunction with marked increase in direct bilirubin (>50% of total) compared to 
baseline and absence of extrahepatic biliary system obstruction and absence of evidence of 
marked accelerated hemolysis [134].  
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       Viral hepatitis (Hepatitis B or C) is usually a consequence of chronic blood transfusion 
therapy. The right upper quadrant (RUQ) syndrome refers to patients with SCD who present with 
pain in the RUQ. Differential diagnosis of this entity includes VOC, cholecystitis, acute hepatic 
sequestration and intrahepatic cholestasis (hepatic crisis). 
Musculoskeletal/Dermatologic Complications 
       Dactylitis (hand-foot syndrome) is inflammation caused by ischemia/ infarction of bone 
and/or bone marrow of the hands and/or feet, resulting in swelling, redness, and pain in affected 
areas. One of the earliest manifestations of SCD, dactylitis is seen primarily in children from 6 
months to 3 years of age, and generally does not occur beyond 5 years of age, due to the lack of 
hematopoietic marrow activity in the hands and feet [135]. 
          Avascular necrosis (AVN) and leg ulcers were described above in the pain syndromes 
section. 
Acute Multiorgan Failure (MOF) 
  This is a catastrophic life threatening complication of SCD in the context of VOC that 
may even occur in patients with otherwise mild SCD [136]. Fever, rapid decrease in Hb level and 
PLT count, nonfocol encephalopathy and rhabdomyolysis are associated with MOF. Prompt and 
aggressive simple blood transfusion or blood exchange transfusion could be lifesaving with rapid 
recovery of organ failure in most cases MOF may occur in patients with history of relatively 
mild disease with little or no evidence of chronic organ damage and may be recurrent. High Hb 
levels in the steady state may be a predisposing factor. 
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 Differential diagnosis of MOF includes ACS and drug overdose. MOF is initially 
heralded by a rapid fall in Hb and PLT counts from baseline. Aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), total and direct bilirubin, serum creatinine, and CPK are 
elevated by the third or fourth day of a VOC. 
Management of Sickle Cell Disease 
Management of SCD in general and its complications in particular follow five major 
approaches (Table 3). These include supportive management, symptomatic treatment, 
preventative management, abortive, and curative approaches to management. Although these 
approaches apply to the disease as a whole, at least one of them applies to each complication as 
well. 
 Supportive Management 
The approach to supportive management is to maintain the essential requirements for 
good health and good quality of life including balanced diet, no obesity, no smoking, minimum 
or no alcohol, no illicit drugs, sleep, hydration, adherence to medical plans and folic acid. Oral 
hydration should be with water not soft drinks.   
 Symptomatic Management 
The goal of symptomatic management is to alleviate the symptoms of the disease as they 
occur. These include: 1) management of pain with nonpharmacologic and/or pharmacologic 
approaches. The latter include opioids, non-opioids and adjuvants. Opioids used are usually 
short-acting for acute pain and long-acting or with extended or sustained release ± short-acting 
for chronic pain; it is important to note that the current national opioid phobia in the USA may, 
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unwittingly, deny opioids to patients who really need them, especially those patients who 
experience recurrent episodes of acute pain such as patients with SCD who are innocent 
bystanders guilty by association within the frame of the current opioid epidemic; 2) RBC 
transfusion for severe anemia, aplastic crisis, acute chest syndrome, acute stroke, multi-organ 
failure, and for the prevention of primary and secondary strokes. Blood transfusion could be 
simple or exchange depending on the nature of the clinical complication; 3) antibiotics for 
prophylaxis or for the treatment of infections; 4) Psycho-social supports as needed. 
 Preventative Management 
The goal of preventive therapy is to ameliorate the clinical picture of SCD in general and 
to decrease the frequency and severity of VOCs in particular. For many years, the major goal of 
primary therapy for SCD was to identify an anti-sickling agent that would prevent or reverse the 
polymerization of sickle Hb in RBCs. Sodium cyanate inhibits polymerization of Hb S in vitro 
but is not beneficial in vivo at levels that provide acceptable toxicity [137]. The use of sodium 
cyanate was associated with peripheral neuropathy and subcapsular cataracts, which prevented 
its use as an antisickling agent. Although the search for beneficial antisickling compounds 
continues, the most promising approaches to prevent the frequency and severity of VOCs include 
the prevention of infection (including antibiotic prophylaxis in infancy and childhood), 
vaccination, avoidance of stressful situations, induction of Hb F production, blood transfusion, 
anti-adhesion therapy and many agents that await confirmation of benefit in clinical trials.  
  Fetal Hemoglobin (Hb F) Induction 
High levels of Hb F have a beneficial effect in patients with SCA. Platt et al. [15] 
demonstrated a significant inverse correlation between the frequency of VOCs and Hb F levels 
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greater than 4%; the higher Hb F level, the milder the disease. Hemoglobin F interferes with the 
polymerization of Hb S; the higher (and the more pancellular) the Hb F level, the lower the 
intracellular concentration of Hb S. Exceptions to this rule include some patients with high Hb F 
level and severe disease and vice versa. 
Among the agents that increase the level of Hb F in humans these, hydroxyurea (HU) as 
monotherapy seems to be the least toxic and most effective [34, 35, 138]. Moreover, HU is the 
only drug studied for efficacy in a relatively large scale, placebo-controlled, randomized clinical 
trial. All the other agents such as decitabine, arginine butyrate, valproic acid, etc. have been 
reported anecdotally to increase Hb F levels. None of the others was used in a controlled phase 
III clinical trial to date. 
Hydroxyurea   
 The molecular mechanism(s) by which HU increases the production of Hb F is (are) 
unknown. Possible mechanisms include perturbations in cellular kinetics and/or recovery from 
cytotoxicity, recruitment of early erythroid progenitors and recruitment of primitive erythroid 
progenitors (BFU-E) that lead to production of Hb F-containing reticulocytes (F-reticulocytes). 
Long-term HU therapy with the maximum tolerated dose (mean dose 21.3 mg/kg) with respect to 
myelosuppression raises Hb F by as much as 15% to 20% (mean 14.9%, range 1.9% to 26.3%). 
 In the randomized, placebo-controlled, double blind Multi-center Study of Hydroxyurea 
(MSH) in SCA, among 299 adult patients with SCA with three or more VOCs per year, HU 
resulted in a significant (p <0.001) reduction in the incidence of VOCs, ACS, and transfusion 
requirement [34, 35]. Hydroxyurea improved the quality of life of the patients taking it [139]. 
There was no difference between the placebo and HU arms in the incidence of death, stroke, or 
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hepatic sequestration. Maximum tolerated doses of HU were not required to reduce the incidence 
of VOCs. Although an increase in Hb F seems to be the obvious and logical explanation for the 
salutary effects of HU, other reasons for its beneficial effects include changes in RBC volume, 
cellular hydration, the cell membrane, and a direct effect on endothelial cells. 
Hydroxyurea and the HUG Trials 
The success of MSH prompted pediatricians to follow suit and determine the efficacy of 
HU in children. A multicenter Phase I/II trial of HU in children with SCA (HUG-KIDS) showed 
that HU therapy is safe for children with SCA when treatment is directed by a pediatric 
hematologist. Treatment of children with HU induced similar laboratory changes as in adults, 
and children could tolerate doses of HU as high as 30 mg/kg/day [140].  
Another 2-year, prospective, multicenter, open-label, single-arm, pilot study 
(Hydroxyurea Safety and Organ Toxicity [HUSOFT]) of HU in very young children with SCA 
showed that HU treatment for infants with SCA is feasible and well tolerated, has hematologic 
efficacy, and may delay functional asplenia [141]. An extension study of the HUSOFT trial, in 
which the dose of HU was increased to up to 30 mg/kg/day, showed that infants with SCA 
tolerated prolonged HU therapy, with sustained hematologic benefits, fewer ACS events, and 
possibly preserved organ function [142]. These early studies in infants and children led to the 
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG).  
The main objective of BABY HUG was to determine if HU can prevent the onset of 
chronic end-organ damage in young children with SCA [143]. The primary endpoints of the 
study were splenic function (determined by qualitative uptake on 99Tc spleen scan) and renal 
function (determined by glomerular filtration rate by 99mTc-diethylene triamine pentaacetic acid 
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[DTPA] clearance). Other endpoints included blood counts, Hb F, chemistry profiles, spleen 
function biomarkers, urine osmolality, neurodevelopment, transcranial Doppler ultrasonography, 
growth, and mutagenicity [143]. A total of 96 patients received HU, and 97 patients received 
placebo. The study confirmed the safety and efficacy of HU therapy for infants with SCA. 
However, treatment with HU showed no significant differences for the primary endpoints: 
splenic function, or glomerular filtration rate [144].  
A different prospective HU study of long-term effects (HUSTLE) showed that HU at 
maximum tolerated dose is associated with a decrease in hyperfiltration in young children with 
SCA [145]. In the BABY HUG trial, treatment with HU was associated with decreased pain (177 
events in 62 patients on HU vs 375 events in 75 patients in the placebo group, P = 0.002), 
decreased dactylitis (24 events in 14 patients on HU vs 123 events in 42 patients in the placebo 
group, P < 0.0001), and decreased incidence of ACS, hospitalizations, and blood transfusions 
[143]. Treatment with HU increased Hb and Hb F and improved hematologic values, decreased 
white blood cell count, and perhaps increased preservation of organ function [143, 146].  
Toxicity was limited to mild to moderate neutropenia. The TCD with Transfusions 
Changing to Hydroxyurea (TWiTCH) trial showed that the transition of pediatric patients from 
transfusion to HU was safe if they met the criteria of the study [147]. Whether this would be the 
same in adults remains to be seen. 
Most recently, a phase 3 randomized clinical trial of L-glutamine powder in getting 
patients with SCA age 5 years and older demonstrated its safety and efficacy in reducing the 
frequency of VOCs that lead to approval by the FDA [148]. The mechanism of action of L-
glutamine is the reduction of oxidative stress in sickle RBC resulting in decreased RBC 
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adhesion, decreased vasoocclusion, and thus, fewer VOCs. Fewer VOCs, in turn, translate into 
decreased mortality in SCD. 
Other Novel Approaches to Therapy 
  A large number of novel preventive therapeutic modalities may have promising roles in 
the management of SCD in general and sickle cell pain in particular. These include, among other 
things, anti-adhesion molecules [149], surfactants [150], levocarnitine, zileuton (a 5-
lipoxygenase inhibitor), green tea [151], aged garlic [151], and herbal extracts [152]. Some of 
these agents are being used on an investigational basis. There are anecdotal reports of success in 
a few patients using some of these agents. However, the efficacy of any of these agents awaits 
proof in Phase III, randomized, double-blind, placebo-controlled trials. Such trials will determine 
if a certain drug is safe, efficacious, and capable of improving the quality of life of treated 
patients. Recently, Singh and Ballas reviewed about 38 drugs that were tried or about to be tried 
in several clinical trials for the prevention of VOCs and related complications [153]. As 
mentioned above, the Phase III trial of senicapoc was terminated because patients who took 
senicapoc had more VOCs than control subjects. A Phase III trial of sildenafil to treat patients 
with elevated tricuspid regurgitant velocity and low exercise capacity was terminated for the 
same reason [154]. 
Abortive management 
The major purpose of this approach is to abort painful VOCs thus preventing them from 
getting worse or precipitating other complications. In a sense, HU achieved this partially by 
reducing the length of hospital stay by 2 days compared to the placebo group [155]. Nitric oxide 
aborted VOCs in the ED but not in hospitalization [156, 157]. 
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Curative Therapies 
Allogeneic Hematopoietic Stem Cell Transplant 
The only curative therapy available at present for SCD in general, and SCA in particular, 
is stem cell transplant. In 1998, 70 patients with SCA had undergone bone marrow transplant 
worldwide. By the end of the 20th century, at least 100 patients with SCA had undergone 
transplant worldwide [158-161]. At that time, most patients were children who received bone 
marrow allografts from siblings with identical human leukocyte antigen (HLA) match and who 
underwent myeloablative conditioning. Although the estimated risk of mortality from HLA-
identical bone marrow transplant was relatively low (~5%), there was some concern regarding 
short-term and long-term toxicity, lack of availability of suitable donors, and barriers to wider 
application [162]. Nevertheless, an interim report on the impact of bone marrow transplant for 
symptomatic SCD found that allogeneic bone marrow transplant establishes normal 
erythropoiesis and is associated with increased growth and stable central nervous system imaging 
results and pulmonary function in most patients [158]. Things have changed for the better since 
2000; some of the barriers have been overcome, and more patients are awaiting appropriate 
donors for transplant. The advent of high-resolution HLA typing, the choice of stem cell sources 
(bone marrow, peripheral blood or cord blood), less toxic conditioning regimens, new 
immunosuppressive agents, facilitated immune reconstitution, and improved supportive care 
have made transplant a more viable option for patients with SCD [163-167]. By 2010, less than 
500 patients with SCD who have undergone transplant have been reported in the Center for 
International Blood and Marrow Transplant Research database [163]. 
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 Allogeneic hematopoietic stem cell transplant is the only curative treatment for SCD at 
present. It is successful in approximately 90% of patients. Unfortunately, conventional 
approaches to transplant are associated with comorbidities including, among other complications, 
infertility, gonadal failure, and chronic Graft Versus Host Disease (GVHD). The use of 
umbilical cord blood has been shown to be as effective as, and possibly safer than, traditional 
bone marrow transplant in children with SCD. The use of nonmyeloablative conditioning 
regimens induce mixed chimerism in transplant recipients, resulting in decreased complications 
of allogeneic hematopoietic stem cell transplant in adults [168-170]. 
Gene Therapy 
Although allogeneic bone marrow transplant can cure SCD, its widespread use is limited 
by the availability of suitable donors and by the complication of GVHD. Gene therapy is an 
alternative approach to achieve a cure of SCD. In simple terms, gene therapy is the introduction 
of normal genes into abnormal cells, either in vitro or in vivo. One potential approach to cure 
SCA is to introduce a functional βA-globin gene into hematopoietic stem cells of the affected 
individual to replace the abnormal βS-globin gene [171]. Methods to achieve this goal include the 
following: 
• Targeted insertion of the transferred gene into the endogenous globin locus by homologous 
recombination, such that the transferred βA-globin gene is located in the proper chromosomal 
environment and expressed at the same level as endogenous β-globin. This would be the ideal 
approach, but it is not yet feasible in hematopoietic stem cells. 
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• Chimeroplasty or gene repair, which introduces chimeric oligonucleotides composed of DNA 
and modified RNA residues into stem cells to direct correction of the mutation in the βS gene 
[172]. 
• Transfer of normal βA-globin gene into hematopoietic cells via retroviral vectors that 
have been modified such that they do not become infective. 
Recent years have witnessed significant progress in the third method mentioned above. 
Basically, this is stem cell gene transfer or autologous transplant, in which the patient’s own 
stem cells are harvested from the bone marrow or peripheral blood, genetically modified, and 
transplanted back into the patient. Genetic modification involves the use of vectors carrying γ-
globin genes for SCD or β-globin genes for β-thalassemia. This approach has already been 
established in mice and was successful in a Phase I/II study, with anticipated benefit for Hb 
disorders. Successful conversion of a patient with β-thalassemia major to transfusion 
independence has been reported [169, 173-176]. 
Conclusion 
Although management of SCA continues to be primarily palliative in nature, there have 
been promising preventative and curative approaches to therapy. Pain management should be 
individualized and coupled with the proper utilization of opioid and nonopioid analgesics in 
order to achieve adequate pain relief. Early recognition and treatment of organ failure minimizes 
morbidity and improves outcome. The use of HU decreases the morbidity and mortality of SCD. 
Cure is possible in selected children and young adults with bone marrow, stem cell or cord blood 
transplantation. Future research seems to focus on refining the molecular and cellular approaches 
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to therapy including gene therapy and mechanisms that prevent the adhesion of sickle RBC to 
vascular endothelium. 
 
Legend to Figure 1 
Sequence of complications of SCA from birth through adult life. Cure is possible in selected 
patients. The mainstay of management in most patients is palliative, with pain management 
being most important. ACS, acute chest syndrome; AVN, avascular necrosis; CVA, 
cerebrovascular accident. (Modified from Ballas SK. Sickle cell disease: current clinical 
management. Semin Hematol 2001;38(4):308; with permission). 
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